PMID: 25735361Mar 5, 2015Paper

Analysis of FHIT gene methylation in egyptian breast cancer women: association with clinicopathological features

Asian Pacific Journal of Cancer Prevention : APJCP
Seham Mahrous ZakiMarwa M Samir S Ahmed

Abstract

Fragile histidine triad (FHIT) gene is a tumor suppressor gene which involved in breast cancer pathogenesis. Epigenetics alterations in FHIT contributes to tumorigenesis of breast cancer. Our objective was to study FHIT promoter region hypermethylation in Egyptian breast cancer patients and its association with clinicopathological features. Methylation-specific polymerase chain reaction was performed to study the hypermethylation of FHIT promoter region in 20 benign breast tissues and 30 breast cancer tissues. The frequency of hypermethylation of FHIT promoter region was significantly increased in breast cancer patients compared to bengin breast disease patients. The Odd ?s ratio (95%CI) of development of breast cancer in individuals with FHIT promoter hypermethylation (MM) was 11.0 (1.22-250.8). There were also significant associations between FHIT promoter hypermethylation and estrogen, progesterone receptors negativity, tumor stage and nodal involvment in breast cancer pateints. Our results support an association between FHIT promotor hypermethylation and development of breast cancer in Egyptian breast cancer patients. FHIT promoter hypermethylation is associated with some poor prognostic features of breast cancer.

References

Mar 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·M FrommerC L Paul
Apr 3, 2003·Nature Reviews. Cancer·Peter W Laird
Jun 6, 2003·The Lancet Oncology·Manel Esteller
Jul 13, 2004·Archives of Biochemistry and Biophysics·Filip GolebiowskiTadeusz Pawelczyk
Jul 21, 2005·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Banu ArunRaheela Ashfaq
Oct 18, 2005·Cancer Letters·Dimitrios IliopoulosKay Huebner
Feb 2, 2006·CA: a Cancer Journal for Clinicians·S Eva Singletary, James L Connolly
Dec 14, 2006·British Journal of Cancer·G TerryJ Cuzick
May 22, 2010·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Feng JingHu Lihua
Jun 22, 2010·TheScientificWorldJournal·Anjilna Wali
Mar 29, 2013·Asian Pacific Journal of Cancer Prevention : APJCP·Xu ChenWu-Ning Mo
Jan 1, 2010·Cancers·Ahmed A S SalemHamza Abbass
Jun 18, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Riham Abdel-Hamid HarounKamal Ali Shalaby
Jul 22, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Wen LiJian-Xin Tang

❮ Previous
Next ❯

Citations

Jun 2, 2016·Epigenetics : Official Journal of the DNA Methylation Society·Catherine L CallahanJo L Freudenheim
Mar 9, 2018·Asia-Pacific Journal of Clinical Oncology·Lisiane Silveira ZavalhiaAdriana Vial Roehe
Jun 13, 2020·Cell Proliferation·Ziyu HeWen Li
Mar 5, 2021·Frontiers in Oncology·Solomon O RotimiBodour Salhia

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Carcinoma, Ductal

Ductal carcinoma is a malignant neoplasm involving the ductal systems of any of a number of organs, such as the mammary glands, pancreas, prostate or lacrimal gland. Discover the latest research on ductal carcinoma here.

Carcinoma, Lobular

Lobular carcinoma is an invasive type of breast cancer in which lobules, areas of the breast that produce milk, undergo malignant transformation. Here is the latest research.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.